AJAbdulhadi Jfri

Abdulhadi Jfri

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Abdulhadi Jfri has a total of 158 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Oral and topical peptides for skin aging: systematic review and meta-analysis of randomized controlled trials

    by Houriah Y. Nukaly, Ibrahim R. Halawani, H. M. Irtaza, Talah Alturkistani, Mohammed Rehab Serafi, Waseem Alhawsawi, Hassan Omar Bogari, Ferdous A. Ahmed, Yara Alhaddad, Asem Shadid, et al.

    Introduction: Skin aging manifests as wrinkles, reduced elasticity, and roughness due to intrinsic and extrinsic factors. Peptide-based therapies enhance collagen synthesis and extracellular matrix integrity. This systematic review and meta-analysis (SRMA) evaluates the efficacy and safety of oral and topical peptides in improving hydration, elasticity, wrinkles, and brightness. Methods: A comprehensive search of MEDLINE, CENTRAL, and Web of Science was conducted following PRISMA guidelines. Randomized controlled trials (RCTs) assessing peptide effects on skin aging parameters were included. The Cochrane Risk of Bias Tool (RoB 2) assessed study quality. Data were synthesized using a random-effects model in RStudio (R version 4.1.1). Conclusion: Nineteen RCTs involving 1,341 participants were analyzed. Peptides, particularly oral formulations, significantly improved hydration and brightness, with a modest pooled effect on wrinkle reduction (MD = 0.27, p = 0.04). Subgroup analysis indicated that this benefit was largely driven by oral polypeptides (MD = 1.5, p = 0.01). While effects on elasticity and density were inconsistent, peptides were well tolerated, with minimal adverse events reported across trials. Overall, peptides appear to be safe, non-invasive anti-aging agents, though larger RCTs with standardized outcomes and histopathologic assessment are warranted. Systematic review registration: identifier CRD420250652779.


  • Open Access

    Growing Evidence for Distinct Clinical Features and Early Diagnostic Age of Cutaneous T-Cell Lymphoma in Saudi Arabia: A Retrospective Study in a Tertiary Care Center

    by Abdulhadi Jfri, Renad Fayez Alharthy, Mariya Yahya Ashqan, Hassan Omar Bogari, Al-Anoud Yousef Alkhashan

    Objectives: To examine trends in Cutaneous T-cell Lymphoma (CTCL) disease presentation in the Western Region of the Kingdom of Saudi Arabia (KSA). Cutaneous T-cell lymphomas (CTCLs) have heterogeneous clinical presentation, and disease characteristics can vary between regions and ethnic groups. Methods: We conducted a local observational study at the Princess Noorah Oncology Center and King Abdulaziz Medical City, Jeddah, with CTCL patients referred to and treated in the Saudi Arabian National Guard facilities from January 2017 to December 2023. Medical records of included patients were retrospectively reviewed. Main outcome measures were demographics and clinical characteristics. Results: The cohort comprised 69 CTCL patients. Mean (SD) age at diagnosis was 43.7 (15.6) years. Male patients outnumbered females by 1.38:1. The most frequently diagnosed form of CTCL was mycosis fungoides (MF), representing 72.5% of patients (50/69). Among MF patients, 87.8% had early-stage disease (stage IA–IIA), and the most common skin presentation was pigmented/erythematous patches (72.0%). Among CTCL lesions, 30.0% were hypopigmented and the mean (SD) diagnostic age in hypopigmented MF was 33.7 (16.4) years. Conclusion: CTCL presented at a relatively young age in Western KSA. We observed a high prevalence of hypopigmented MF and reported a young mean diagnostic age among hypopigmented MF patients. Our study highlighted the regional variation in CTCL presentation and the importance of investigating trends to facilitate diagnosis and treatment.

  • Open Access

    A case of recurrent pyoderma gangrenosum injection site reaction triggered by Maveropepimut-S (previously known as DPX-Survivac) in a patient undergoing immunotherapy for ovarian cancer: A case report

    by David Nassim, Ali Alajmi, Abdulhadi Jfri, Zeinah AlHalees, Meghan Kanou, Ivan V. Litvinov

    Pyoderma gangrenosum is a rare neutrophilic dermatosis often associated with systemic inflammatory or malignant conditions. We report a case of recurrent pyoderma gangrenosum injection site reactions following subcutaneous Maveropepimut-S (previously known as DPX-Survivac), an anti-cancer vaccine, in a 31-year-old woman undergoing immunotherapy for stage 3C ovarian cancer. The diagnosis was confirmed histologically and clinically after repeated ulcerative lesions developed at injection sites. The lesions showed a rapid response to corticosteroid therapy. This case highlights the importance of recognizing pyoderma gangrenosum as a potential cutaneous adverse event in immunotherapy treatments and suggests that timely dermatologic evaluation may help avoid delays in diagnosis and treatment.

  • Exosomes and extracellular vesicles as biomarkers in dermatology and systemic inflammatory diseases: Emerging clinical applications

    by Houriah Y. Nukaly, Husna Irfan Thalib, Atheer G. Almutairi, Fatima Shafiya Ali, Shyma Haidar, Hala Abdullah Almusa, Sariya Khan, Ayesha Hanin Shaikh, Ghassan Barnawi, Zainab Ridha, et al.


  • Open Access

    Familial Annular Erythema Effectively Responded to Phototherapy: A Case Report of an Extremely Rare Entity and Literature Review

    by Waseem Alhawsawi, Houriah Nukaly, Abdulhadi Jfri, Razan S. Al-Luhaibi, Abdulmajeed Aljarallah, Sarah M. Fageeh, Khalid Al Hawsawi

    Introduction: Familial annular erythema is the inherited form of erythema annular centrifugum, in an autosomal dominant fashion. It is an extremely rare cutaneous condition characterized by asymptomatic or mildly itchy annular, arcuate or polycyclic erythematous plaques that appears few days after birth with no systemic manifestations. Histopathological features are consistent with erythema annular centrifugum. To this date, only five families have been reported to the literature. Case Presentation: Herein, we report a family with three generations of affected individuals. The index patient was a 23-year-old female, presented with mildly itchy non-scaly annular and arcuate erythematous plaques that appeared since birth. Her paternal grandmother, father, sister and two male cousins have similar condition. Review of system and laboratory workup was unremarkable. Skin biopsy showed focal compact orthohyperkeratosis, spongiosis, basal cell degeneration, prominent papillary edema with moderate superficial and deep perivascular eosinophilic infiltrate. The index patient was started on narrowband ultraviolet B therapy and showed complete clearance for at least 3 months. Conclusion: This extremely rare entity is not known to be associated with other organ involvement, apart from the skin. It poses diagnostic difficulty as it resembles other annular conditions during infancy. The presence of similar cases within her family underscores the genetic component of this condition, warranting further investigation and discussion. Possible effective therapeutic options include phototherapy.

  • Open Access

    The Predictive Factors of Acne Scarring and Post-Inflammatory Hyperpigmentation: A Retrospective Cohort Study

    by Awadh Alamri, Dhaii Alzahrani, Ghadi Alharbi, Rami Jan, Lulu Abdullah Alsubaie, Amjad Alghamdi, Amal H Abualola, Abdulhadi Jfri

    Introduction: Acne vulgaris, a prevalent dermatological condition, often results in long-term complications such as scarring and hyperpigmentation. While extensive research has focused on treatment modalities, there is a notable gap in understanding the factors contributing to the development of acne scarring and post-inflammatory hyperpigmentation (PIH). Purpose: This study was conducted to identify the factors contributing to the development of acne scarring and post-inflammatory hyperpigmentation (PIH). Patients and Methods: This retrospective cohort study, conducted at King Abdulaziz Medical City, Jeddah, Saudi Arabia, analyzed data from patients with acne vulgaris between 2016 and 2023 using the hospital’s health information system, BESTCare. Statistical analysis was performed using RStudio (R version 4.3.1). We constructed a multivariable, multinomial logistic regression model to assess the independent predictors of four acne complication groups; no scarring/PIH, scarring alone, PIH alone, and acne scarring with PIH. Results: Among 417 analyzed participants, 95 participants had acne scarring (22.8%), 93 participants had PIH alone (22.3%), and 151 participants had both acne scarring with PIH (36.2%), and only 78 participants did not develop scarring or PIH (18.7%). Isotretinoin use and papules acne were associated with increased risk of acne complications. While adapalene gel was protective against acne scarring only. Conclusion: This retrospective study sheds light on factors influencing acne scarring and PIH among Acne Vulgaris patients. Our findings provide valuable insights for tailoring interventions and advancing our understanding of acne vulgaris complications in the future.


  • Open Access

    The Landscape of Cutaneous T-Cell Lymphoma (CTCL) in the Middle East and North Africa (MENA) and the Establishment of the MENA CTCL Working Group

    by Rasha Abdel Tawab, Jihan Rajy, Salah Abdallat, Muna Abdula Almurrawi, Khalil Al Farsi, Jehad Alassaf, Hussni Alhateeti, Atlal Al Lafi, Reem El Bahtimi, Abdulhadi Jfri, et al.

    The high cancer burden in the Middle East and North Africa (MENA region) is coupled with an increasing cancer incidence. While the MENA region constitutes 6% of the world’s population, it remains underrepresented in clinical trials. Cutaneous T-cell lymphomas (CTCLs) represent a heterogeneous group of rare extranodal non-Hodgkin lymphomas with variable clinical presentation. In the MENA region, where darker skin colors are more common than in the West, CTCL generally presents at a younger age and with distinct clinical features that necessitate special expertise and management across disciplines: rare forms of CTCL are more common (hypo- and hyperpigmented MF) and a higher prevalence of pediatric MF is noticed. The multidisciplinary approach to cancer management is growing worldwide and is necessary for the comprehensive management of CTCL. The MENA CTCL group was established with the aim of creating a collaborative environment for the diagnosis and treatment of CTCL in the region. Its first meeting was held in May 2023. The group plans to increase the global representation of the MENA region and establish CTCL registries and patient advocacy groups in the region.


  • Top Cited Papers
    Open Access

    Oral Lichen Planus: A Narrative Review Navigating Etiologies, Clinical Manifestations, Diagnostics, and Therapeutic Approaches

    by Houriah Yasir Nukaly, Ibrahim R. Halawani, Saja Mohammed S. Alghamdi, Araa Ghanem Alruwaili, Alhanouf Binhezaim, Rana Ali A. Algahamdi, Rayan Abdullah J. Alzahrani, Faisal Saad S. Alharamlah, Shahad Hamad S. Aldumkh, Hamad Majid A. Alasqah, et al.

    Background/Objectives: Oral Lichen Planus (OLP) is a common immune-mediated inflammatory disorder affecting the oral mucosa, impacting 0.5% to 2% of the global population, primarily middle-aged women. Immunological dysregulation is a key factor in OLP’s pathogenesis, involving CD4+ T helper and CD8+ T cytotoxic cells. The World Health Organization (WHO) classifies OLP as a potentially malignant disorder, with a risk of oral squamous cell carcinoma (OSCC) developing in up to 2% of lesions. This narrative review aims to provide a comprehensive overview of the etiopathogenesis, clinical manifestations, diagnostic criteria, and therapeutic strategies for OLP, informing clinical practice and guiding future research. Methods: A review of the literature from the PubMed and Google Scholar databases was conducted up to December 2023, focusing on studies addressing the etiopathogenesis, diagnosis, clinical manifestations, and treatment of OLP. Results: OLP’s pathogenesis is driven by immune dysregulation, with CD4+ and CD8+ cells playing crucial roles. Clinically, OLP presents as reticular, erosive, bullous, and plaque-like lesions. Diagnosis relies on clinical examination, histopathology, and direct immunofluorescence. Recent advancements in diagnostic markers and imaging techniques have improved detection and monitoring. Treatment primarily involves corticosteroids, but novel therapies such as curcumin, retinoids, and laser therapy are increasingly used for their effectiveness and reduced side effects. These treatments show promise in symptom reduction and recurrence prevention, although long-term data are needed. Conclusions: Regular screenings and biopsies are essential due to OLP’s likelihood of malignant transformation. This study urges further investigation into long-term results, improved diagnostic techniques, and evidence-based treatment regimens.


  • Open Access

    The efficacy and safety of minocycline, metronidazole, ivermectin, and azelaic acid in moderate-to-severe papulopustular rosacea: A systematic review and network meta-analysis

    by Esraa A. Shaheen, Yara E. Aljefri, Abdullah A. Ghaddaf, Khalid M. Alshareef, Abeer K. Alhindi, Narin F. Alanazi, Anwar R. Alrashidi, Abdulhadi Jfri


  • Open Access

    Giant cell lichenoid dermatitis within healed varicella zoster site

    by Yara Alghamdi, Bashaer Almahdi, Sahar Alsifri, Hassan Huwait, Abdulhadi Jfri

    Key Clinical Message: There are dermatoses that arise within healed zosteriform sites, such as granulomas annulare, acneiform eruptions, psoriasis, lichen planus, and giant cell lichenoid dermatitis “GCLD.” Nonetheless, graft‐versus‐host disease should be considered and ruled out, especially in patients post‐bone marrow transplant. Herein, we report a case of GCLD manifesting within healed zosteriform sites.